2020•Default Digital Object GroupRequires access

Pembrolizumab Monotherapy Demonstrates PFS Benefit Over Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma

Author information unavailable

Abstract

Pembrolizumab monotherapy demonstrated a progression-free survival (PFS) benefit over brentuximab vedotin (BV) in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma, according to the results from the phase III international KEYNOTE-204 trial (Abstract 8005).

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Brentuximab vedotin, Pembrolizumab, Oncology, Internal medicine, Medicine, Classical Hodgkin lymphoma, Refractory (planetary science), Lymphoma